Exploring the role of BRCA1, BRCA2 and RAD51 as biomarkers for breast cancer

Radiotherapy and Oncology

Volumn 90, Issue 1, 2009, Pages 161-162

  Ziogas, D ^a   Liakakos, T ^a   Lykoudis, E ^a   Fatourou, E ^a   Roukos, D H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; RAD51 PROTEIN; TUMOR MARKER;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC RISK; LETTER; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; HUMANS; MUTATION; RAD51 RECOMBINASE; TUMOR MARKERS, BIOLOGICAL;

EID: 58149231352     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.02.020     Document Type: Letter

References (10)

1. Pennisi E. Breakthrough of the year. Human genetic variation. Science 318 (2007) 1842-1843
2. Roukos D.H., Murray S., and Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6 (2007) 308-312
3. Roukos D.H. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8 (2008) 29-39
4. Roukos D.H. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357 (2007) 1555-1556
5. Roukos D.H., and Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4 (2007) 578-590
6. Fatouros M., Baltoyiannis G., and Roukos D.H. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15 (2008) 21-33
7. Roukos D.H. Linking contralateral breast cancer with genetics. Radiother Oncol 86 (2008) 139-141
8. Agnantis N.J., Paraskevaidis E., and Roukos D. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance. Ann Surg Oncol 11 (2004) 1030-1034
9. Roukos D.H. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358 (2008) 197 [author reply 198]
10. Söderlund K., Skoog L., Fornander T., and Askmalm M.S. The BRCA1/BRCA2/Rad51 complex is a prognostic and predictive factor in early breast cancer. Radiother Oncol 84 (2007) 242-251